Quantum SI

Quantum SI

QSI
United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

QSI · Stock Price

USD 0.98-0.35 (-26.24%)
Market Cap: $193.6M

Historical price data

Overview

Quantum-Si's mission is to make single-molecule protein sequencing accessible to every lab, thereby unlocking the proteome. The company has achieved this by commercializing the Platinum Pro, the world's first benchtop next-generation protein sequencing (NGPS) instrument, which uses kinetic signatures for real-time, single-amino-acid resolution. Its strategy leverages a platform model, selling instruments and consumables, while exploring high-value applications in ultrasensitive protein detection (USPD) for diagnostics through partnerships. Quantum-Si aims to become the foundational technology for the burgeoning field of proteomics.

Genetics & Genomics

Technology Platform

Quantum-Si's platform integrates semiconductor technology, single-molecule fluorescence, and kinetic analysis to enable next-generation protein sequencing (NGPS) and ultrasensitive protein detection (USPD) on a benchtop instrument.

Opportunities

The primary opportunity lies in democratizing proteomics by displacing complex mass spectrometry in research labs and enabling new applications in biopharma development.
The long-term, high-value opportunity is in clinical diagnostics through its Ultrasensitive Protein Detection (USPD) platform, which could open a multi-billion dollar market for biomarker detection.

Risk Factors

Key risks include slow adoption of its novel protein sequencing technology against entrenched mass spectrometry, failure to successfully commercialize and scale instrument sales, intense competition from both established and emerging proteomics companies, and the high cash burn rate inherent in platform development without near-term profitability.

Competitive Landscape

Quantum-Si competes directly with mass spectrometry giants (Thermo Fisher, Bruker) in research proteomics, with ultra-sensitive immunoassay leaders (Quanterix) in diagnostics, and with a cohort of well-funded private companies (e.g., Nautilus Biotechnology) developing alternative protein analysis platforms. Its differentiation hinges on single-molecule kinetic sequencing and benchtop accessibility.